Form 4: Acumen COO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' COO, Russell Barton, sold common stock to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

Summary

• Russell Barton, Chief Operating Officer of Acumen Pharmaceuticals, Inc. (ABOS), reported sales of common stock.
• The transactions occurred on January 21, 2026, and January 22, 2026.
• A total of 2,315 shares were sold on January 21, 2026, at a weighted average price of $1.806 per share, with prices ranging from $1.7600 to $1.8700.
• An additional 462 shares were sold on January 22, 2026, at a price of $1.84 per share.
• These sales were 'sell to cover' transactions to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Barton on August 30, 2024.
• Following these transactions, Mr. Barton beneficially owns 205,092 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine 'sell to cover' transaction by an insider to satisfy tax obligations under a pre-arranged 10b5-1 plan. This is a non-discretionary event and does not reflect a change in management's outlook on the company.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not discretionary sale.

Negatives

• A reduction in direct insider ownership, though for a routine tax purpose.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific industry context. Such 'sell to cover' transactions are common across all industries when restricted stock units vest.

Comparison to Industry Standards

• 'Sell to cover' transactions are standard practice for executives to meet tax obligations upon the vesting of equity awards.
• The use of a Rule 10b5-1 plan aligns with best practices for insiders to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: Minor, routine reduction in insider ownership for tax purposes, generally not indicative of a change in confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Russell Barton, Chief Operating Officer, Insider Trading, Form 4, Stock Sale, Sell to Cover, Tax Withholding, Restricted Stock Units, 10b5-1 Plan